Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 19/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | MARK3 | P27448 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4858809 | 0.85 | CHEK1 (0.60) | CHEK1PDPK1MAPK8AURKARPS6KB1 | |
| SCHEMBL4857292 | 0.85 | CHEK1 (0.60) | CHEK1PDPK1JAK2MAPK8AURKA | |
| SCHEMBL4853101 | 0.84 | CHEK1 (0.52) | CHEK1PDPK1AURKARPS6KB1CDK2 | |
| SCHEMBL4848035 | 0.83 | CHEK1 (0.47) | CHEK1PDPK1JAK2MAPK8AURKA | |
| SCHEMBL4857711 | 0.82 | CHEK1 (0.62) | CHEK1 | |
| SCHEMBL4849452 | 0.82 | CHEK1 (0.63) | CHEK1 | |
| SCHEMBL4856416 | 0.81 | CHEK1 (0.64) | CHEK1PDPK1JAK2MAPK8AURKA | |
| SCHEMBL4855160 | 0.80 | CHEK1 (0.71) | CHEK1PDPK1JAK2MAPK8AURKA | |
| SCHEMBL4856996 | 0.78 | CHEK1 (0.48) | CHEK1PDPK1JAK2MAPK8AURKA | |
| SCHEMBL4855860 | 0.78 | CHEK1 (0.61) | CHEK1PDPK1JAK2MAPK8AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | claimed |
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | CHEK1 38/4885PDPK1 118/4885JAK2 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.